Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triple Therapy (Peginterferon Alfa-2a, Ribavirin, Amantadine) vs Standard Therapy in Chronic Hepatitis C Genotype 1
NCT00127777Phase 4Unknown
- Sponsor
- Saarland University Medical Center
- Start
- Jul 2002
- Modality
- Small Molecules
01
Overview
Phase 4, randomised trial of amantadine in hepatitis C (HCV) (2 arms), sponsored by Saarland University Medical Center. Primary endpoint: Sustained Virological Response at 24 Weeks Post-Therapy. Status: unknown.
02
Drugs
amantadine
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00127777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00127777.